ホーム › トリプルネガティブ乳がん › オハイオ › Columbus
Columbus、OHにおけるトリプルネガティブ乳がんの臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、トリプルネガティブ乳がんに関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
被験者募集中第1相
- Ohio State University Comprehensive Cancer Center, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- The Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Local Institution - 0102, Columbus
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Ohio State University, Columbus
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
被験者募集中第3相
- Ohio State University CRS, Columbus
- Ohio Health Research Institute, Columbus
- Anita Stewart Oncology Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
被験者募集中第1/2相
- Ohio State University, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
被験者募集中
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- The Ohio State University (OSU) Wexner Medical Center, Columbus
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
被験者募集中第2相
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
被験者募集中第2相
- Ohio State University Medical Center, Columbus
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
被験者募集中
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- The Ohio State University, Columbus
他の都市におけるトリプルネガティブ乳がんの試験
- Houston, TX42件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Los Angeles, CA27件の研究
- Boston, MA26件の研究
- San Antonio, TX23件の研究
- St. Louis, MO21件の研究
- Arlington, VA20件の研究
- Atlanta, GA20件の研究
- Dallas, TX18件の研究
- Chicago, IL16件の研究
- Grand Rapids, MI15件の研究
Columbusにおける他の研究
- 非小細胞肺癌57件の研究
- 乳がん40件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
- 大腸癌24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。